1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

Mineralys Is In A Close Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Mineralys Therapeutics
Mineralys Therapeutics (Shutterstock)

Mineralys’s lorundrostat has demonstrated its potential to reduce blood pressure in patients with hypertension again, as the aldosterone synthase inhibitor has achieved a third clinical win in recent months giving close fight to AstraZeneca’s baxdrostat.

Key Takeaways
  • Lorundrostat met key efficacy and safety endpoints in the Phase II Explore-CKD trial, showing blood pressure and kidney benefits. 

      The biotech firm has announced positive topline data from its Phase II Explore-CKD trial evaluating the safety and efficacy of...

      Read the full article – start your free trial today!

      Join thousands of industry professionals who rely on Scrip for daily insights

      • Start your 7-day free trial
      • Explore trusted news, analysis, and insights
      • Access comprehensive global coverage
      • Enjoy instant access – no credit card required
      Start Free Trial

      Already a subscriber?

      More from Clinical Trials

      Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

      Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

      Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

       
      • By Alaric DeArment

      The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

      Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

       
      • By Andrew McConaghie

      The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

      Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

       
      • By Kevin Grogan

      Comes Days After PDUFA Pushback For GSK's Blenrep.

      More from Therapy Areas

      GSK’s Blenrep US Setback Could Go From Bad To Worse

       
      • By Sushmita Panda

      With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

      Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

       
      • By Andrew McConaghie

      The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

      More Pressure on Elevidys As The EU’s CHMP Says ‘No’

       
      • By Alexandra Shimmings

      Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.